Tool can identify harmful medications in older adults with cancer, study finds Researchers analysed patient record data to identify patients that were prescribed one or more potentially inappropriate medications, which are considered to be high-risk for older adults.…
Major step forward as bladder cancer treatment approved in England The National Institute for Health and Care Excellence estimates that more than 1,200 people each year in England could benefit from the enfortumab vedotin and pembrolizumab combination therapy.…
Patients with head and neck cancer to be fast-tracked into NHS vaccine trial The investigational mRNA cancer vaccine will be trialled across 15 NHS hospitals over 12 months, the third cancer vaccine trial to be run through the NHS Cancer Vaccine Launch Pad.…
Immunotherapy plus chemotherapy approved for endometrial cancer Immunotherapy drug pembrolizumab (Keytruda: Merck Sharp and Dohme) could benefit 2,100 people with advanced womb cancer.…
NICE approves expanded access to early breast cancer treatment The National Institute for Health and Care Excellence estimates that its updated guidance will make ribociclib available to a further 5,700 patients.…
Pharmacies to trial test for risk of oesophageal cancer NHS England said that the “heartburn health check” could help transfer care from hospitals to the community, as part of the NHS ten-year health plan.…
NICE recommends ‘breakthrough’ therapy for blood cancer Belantamab mafodotin combination therapy is a second-line treatment option for multiple myeloma that could benefit around 1,500 people.…
Supporting pharmacists in improving the care delivered for people with cancer The Pharmaceutical Journal has launched a cancer ‘hub page’ and educational resources on blood cancer as part of continued partnership with BeiGene.… Promotional content
NICE reverses draft guidance to recommend targeted therapy for patients with advanced bowel cancer The National Institute for Health and Care Excellence said the treatment should be available on the NHS after the manufacturer provided additional clinical evidence.…
NICE recommends capivasertib for advanced breast cancer Clinical trial results revealed that capivasertib, taken with fulvestrant, can provide advanced breast cancer patients with an additional four months before their cancer progresses.…
